Marvell's $115 Billion Lumentum Deal: A 23.9% Premium That Melted Into a Discount in Two Sessions

The agreement and plan of merger is dated Nov. 1, 2026 and was announced the following morning. It is a two-step structure in which Lumentum first becomes a wholly owned subsidiary of Marvell, then merges into a new parent. Marvell shareholders keep roughly 67% of the combined company on a fully diluted basis, which hands Lumentum holders roughly a third of the business they are buying into. Marvell chief executive Matt Murphy stays chairman and CEO, and three Lumentum directors, including chief executive Michael Hurlston, join the Marvell board.

The $1,132 per-share figure was struck off Marvell's Oct. 28 close of roughly $251.66. After the talks were reported, Marvell fell 13.2% to $218.34 on Oct. 29 and about another 10% on Oct. 30 to roughly $196. Applying the unchanged 4.500 ratio, the same offer now values Lumentum at $982, then about $882, then roughly $862. That cuts what Marvell is paying by about 22% in two sessions, and it does so entirely through the acquirer's own de-rating rather than through any renegotiation.

On reported numbers, Marvell is paying 38 times Lumentum's fiscal 2026 revenue for a business growing faster than anything else in AI connectivity. Lumentum turned over $3.01 billion in fiscal 2026 and $3.74 billion in the twelve months to Sept. 26, 2026, so the $115 billion price is 30.7 times the most recent trailing revenue and 18.0 times the annualized run-rate implied by its own second-quarter guidance. Marvell, on $9.45 billion of trailing revenue and a $173.4 billion enterprise value, trades at 18.3 times sales. In other words, Marvell pays roughly 1.7 times its own trailing multiple and roughly the same multiple on next year's run-rate — the entire gap is a bet that Lumentum's ramp is real.

The dilution arithmetic is less forgiving than the strategic logic. Consensus normalized earnings per share for Marvell go from $2.84 for the year ended Jan. 31, 2026 to $7.33 for the year ending Jan. 31, 2028. Handing over roughly 450 million new shares — the arithmetic implied by a 4.500 ratio against Lumentum's 101.7 million diluted count — against Marvell's 921.2 million diluted shares, and adding Lumentum's earnings on the mid-point of its own guidance, roughly $2.5 billion of annualized non-GAAP net income at45.5% non-GAAP operating margins, dilutes the combined earnings base by about 8% before a single dollar of synergy is counted.

The scarcity is not a story about multiple expansion; it is a capacity fact. Lumentum chief executive Michael Hurlston said in October that the companycannot meet about 70% of demand for some products through next year, with capacity sold out through early 2029. Laser demand exceeds supply by more than 30%, and the binding constraint has moved upstream to indium-phosphide substrates, where Lumentum has prepaid AXT $87 million for minimum annual capacity through the end of 2031.

The most important structural fact is that NVIDIA owns a stake in every side of the photonics trade — $2 billion in Lumentum, $2 billion in Coherent and $2 billion in Marvell inside a single month. For Marvell shareholders that is a quiet subsidy: the company is buying the asset its most important customer has already underwritten, and Marvell itself now designs the accelerators that consume the lasers it is buying. For Coherent and the merchant module vendors, it is the beginning of a squeeze: the customer has the same optics supplier on three sides of the table.

For hyperscalers this is a mixed blessing. A combined Marvell and Lumentum can sell an accelerator with its optics attached, which shortens design cycles and shifts the negotiation for laser capacity from a component vendor to a systems vendor. It also collapses the number of vendors a hyperscaler must negotiate with, at a time when two customers each accounted for more than 10% of Marvell's fiscal 2026 revenue and the top ten were 82%. Fewer vendors means less optionality at the margin, which is exactly the point of the deal for the seller and exactly the risk for the buyer.

The strategic case is real. Lumentum owns a sold-out laser and optical-engine business that no custom-silicon vendor could previously buy, Marvell owns the accelerators that consume it, and the combination converts a component shortage into an integrated product. The financial case is narrower than the $115 billion headline: Marvell is paying roughly 1.7 times its own trailing sales multiple for assets growing at more than 100%, funding it with stock that has fallen about 22% since the talks leaked, and handing a third of the company to the sellers. Two clocks decide the outcome — the first is the Chinese regulatory review, with the outside date running to Aug. 1, 2028, and the second is the synergy ledger. Until both are visible, Marvell shareholders pay for the same scarce photons twice, once in the 38 times sales handed to Lumentum holders and once in the multiple compression in their own share price.